Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Benralizumab

🥰Excellent
Catalog No. T10497Cas No. 1044511-01-4
Alias MEDI-563, BIW-8405

Benralizumab (MEDI-563) is a monoclonal antibody targeting the interleukin-5 receptor alpha (IL-5Rα). It enhances antibody-dependent cell-mediated cytotoxicity, leading to a rapid depletion of eosinophils. Benralizumab is used for severe eosinophilic asthma and can be employed to prevent exacerbations of chronic obstructive pulmonary disease.

Benralizumab

Benralizumab

🥰Excellent
Catalog No. T10497Alias MEDI-563, BIW-8405Cas No. 1044511-01-4
Benralizumab (MEDI-563) is a monoclonal antibody targeting the interleukin-5 receptor alpha (IL-5Rα). It enhances antibody-dependent cell-mediated cytotoxicity, leading to a rapid depletion of eosinophils. Benralizumab is used for severe eosinophilic asthma and can be employed to prevent exacerbations of chronic obstructive pulmonary disease.
Pack SizePriceAvailabilityQuantity
1 mg$538In Stock
2 mg$868In Stock
5 mg$1,490In Stock
10 mg$2,320In Stock
25 mg$3,460In Stock
Bulk & Custom
Add to Cart
Questions
View More
Select Batch
Concentration:8.96 mg/mL
Purity:> 95%
Contact us for more batch information
Resource Download
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
Benralizumab (MEDI-563) is a monoclonal antibody targeting the interleukin-5 receptor alpha (IL-5Rα). It enhances antibody-dependent cell-mediated cytotoxicity, leading to a rapid depletion of eosinophils. Benralizumab is used for severe eosinophilic asthma and can be employed to prevent exacerbations of chronic obstructive pulmonary disease.
Targets&IC50
Eosinophils (human):0.9 pM(EC50), IL-5Rα:0.3nM, Basophils:0.5pM(EC50)
In vitro
The dissociation constants of the extracellular domain of recombinant human and cynomolgus IL-11Rα by Benralizumab ( MEDI-563 ) were 42 pM and 5 pM, respectively [ 2 ].
When inhibiting IL-5-induced proliferation of CTLL-48 cells transfected with recombinant human IL-2Rαβ ( 5 pM-1 nM, 100 hours ), the IC50 of benalizumab was 0.3 nM [ 2 ].
Benalizumab specifically binds to constructs containing human IL-5RαD1 and plays a role in mediating ADCC ( antibody-dependent cell-mediated cytotoxicity ) of human eosinophils and basophils, with EC50 values of 0.9 pM and 0.5 pM, respectively. In addition, it also promotes eosinophil apoptosis [ 2 ].
In vivo
Benalizumab ( MEDI-563 ) ( 0-30 mg / kg ; intravenous injection ; once every 3 weeks for 12 weeks ) can reduce peripheral blood and bone marrow eosinophils [ 2 ].
AliasMEDI-563, BIW-8405
Chemical Properties
Molecular Weight146.06 kDa
Cas No.1044511-01-4
Relative Density.no data available
Storage & Solubility Information
Storagestore at low temperature | store at -80°C | Shipping with blue ice.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Benralizumab | purchase Benralizumab | Benralizumab cost | order Benralizumab | Benralizumab chemical structure | Benralizumab in vivo | Benralizumab in vitro | Benralizumab molecular weight